According to the current analysis of Reports and Data, the global Dystrophin Market was valued at 0.60 billion in 2018 and is expected to reach USD 13.02 billion by year 2026, at a CAGR of 47% percent. The growth of the dystrophin market is more in countries such as U.S, Austria, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, Norway, Portugal, Slovakia, South Korea, and the United Kingdom; where key muscular dystrophy drugs are available in the market.
The market is characterized by the entry of a large number of players that includes emerging companies, as well as healthcare giants. The primary factor, for the focus of market players, is the unaddressed demand for treatment of muscular dystrophy diseases for a long time. There are over 35 companies engaged in clinical trials for the launch of novel therapeutics for the treatment of DMD. However, owing to stringent regulation across the globe for drug approval, very few drug candidates have received approval by medicine regulatory bodies such as the US Food and Drug Administration (FDA), and European Commission.
North America is expected to have a high demand on account of the product launches in the U.S. In 2017, North America dominated the dystrophin market in 2017, with a market share of 52.6; followed by Europe. The North America dystrophin market is estimated to be worth USD 45.6 billion by 2025. Factors such as high incidence of muscular dystrophy in the region, accelerated FDA approval of drug in the region, favorable funding scenario for research & development in field of DMD, high healthcare expenditure potential among the North American population, availability of medical reimbursement in the region are among key factors supporting the growth of dystrophin market in North America.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1063
The report provides a panoramic view of the market and insights that will help formulate better business decisions. In addition to that, the study helps well-established companies and players gain a deeper understanding of the market and make informed decisions. The report also discusses in detail about the key factors influencing the market growth.
Key companies operating in the market include:
PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis Pharmaceuticals among others. PTC Therapeutics has a market presence through its muscular dystrophy drugs under the brand name, Emflaza, and Translarna. As of 2017, PTC Therapeutics dominated the market followed by Sarepta Therapeutics.
The report covers an extensive analysis of the key market players in the market along with their business overview, expansion plans, and strategies. The report also focuses on recent strategic alliances in the market including mergers and acquisitions, joint ventures, partnerships, agreements, corporate and government deals, product launches, and brand promotions, among others.
On basis of product types and application offered by the Dystrophin industry, the market is segmented into:
Product Outlook (Revenue, USD Million, 2016 – 2026)
Approach Outlook (Revenue, USD Million, 2016 – 2026)
- Exon Skipping
- Anti-Inflammatory Therapy
- Stop Codon Read-Through
- Others Approaches
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1063
The report aims to provide a better understanding of the market dynamics and the workings of the industry on a global level. To gain a deeper understanding of the industry, the global Dystrophin market is further segmented on the basis of key geographical regions such as North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The report also offers a country-wise analysis to provide crucial insights into market size, market growth, market revenue growth, and economic growth in each region.
The regional analysis covers:
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of MEA
To know more about the report @ https://www.reportsanddata.com/report-detail/dystrophin-market
Benefits of Dystrophin Market Report:
- Panoramic overview of the opportunities and risks in the Dystrophin sector
- Study of recent innovations and developments in the industry
- Comprehensive study of the growth pattern of the Dystrophin industry
- In-depth assessment of the competitive landscape of the key players of the Dystrophin industry
- Analysis of the Dystrophin market drivers, constraints, and opportunities
- Assessment of technological developments and latest trends of the industry
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1063
Thank you for reading our report. For customization or further inquiry, please get in touch with us. Our team will ensure the report is tailored according to your requirements.
Explore our related report from different Publications:
Bone Growth Stimulator Market @ https://www.biospace.com/article/bone-growth-stimulator-market-size-to-reach-usd-1-788-54-million-in-2028-reports-and-data/
Cerebrospinal Fluid (CSF) Management @ https://www.biospace.com/article/cerebrospinal-fluid-csf-management-market-size-to-reach-usd-2-3-billion-in-2028-reports-and-data/
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]